Literature DB >> 33430419

Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction.

Thomas M Barber1,2, Ioannis Kyrou1,2,3, Harpal S Randeva1,2,3, Martin O Weickert1,2,4.   

Abstract

Obesity mediates most of its direct medical sequelae through the development of insulin resistance (IR). The cellular effects of insulin occur through two main postreceptor pathways that are the phosphatidylinositol 3-kinase (PI3-K) and the mitogen-activated protein kinase (MAP-K) pathways. Obesity-related IR implicates the PI3-K pathway that confers the metabolic effects of insulin. Numerous and complex pathogenic pathways link obesity with the development of IR, including chronic inflammation, mitochondrial dysfunction (with the associated production of reactive oxygen species and endoplasmic reticulum stress), gut microbiota dysbiosis and adipose extracellular matrix remodelling. IR itself plays a key role in the development of metabolic dysfunction, including hypertension, dyslipidaemia and dysglycaemia. Furthermore, IR promotes weight gain related to secondary hyperinsulinaemia, with a resulting vicious cycle of worsening IR and its metabolic sequelae. Ultimately, IR underlies obesity-related conditions such as type 2 diabetes mellitus (T2D) and polycystic ovary syndrome (PCOS). IR also underlies many obesity-related malignancies, through the effects of compensatory hyperinsulinaemia on the relatively intact MAP-K insulin pathway, which controls cellular growth processes and mitoses. Furthermore, the emergent data over recent decades support an important role of obesity- and T2D-related central IR in the development of cognitive dysfunction, including effects on hippocampal synaptic plasticity. Importantly, IR is largely reversible through the optimisation of lifestyle factors that include regular engagement in physical activity with the avoidance of sedentariness, improved diet including increased fibre intake and sleep sufficiency. IR lies at the key crossroad between obesity and both metabolic and cognitive dysfunction. Given the importance of IR in the pathogenesis of many 21st century chronic diseases and its eminent reversibility, it is important that we all embrace and facilitate optimised lifestyles to improve the future health and wellbeing of the populace.

Entities:  

Keywords:  cognitive dysfunction; insulin resistance; metabolic dysfunction; obesity

Year:  2021        PMID: 33430419     DOI: 10.3390/ijms22020546

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  14 in total

Review 1.  Obesity I: Overview and molecular and biochemical mechanisms.

Authors:  Robert H Lustig; David Collier; Christopher Kassotis; Troy A Roepke; Min Ji Kim; Etienne Blanc; Robert Barouki; Amita Bansal; Matthew C Cave; Saurabh Chatterjee; Mahua Choudhury; Michael Gilbertson; Dominique Lagadic-Gossmann; Sarah Howard; Lars Lind; Craig R Tomlinson; Jan Vondracek; Jerrold J Heindel
Journal:  Biochem Pharmacol       Date:  2022-04-05       Impact factor: 6.100

2.  Assessing Insulin Sensitivity and Postprandial Triglyceridemic Response Phenotypes With a Mixed Macronutrient Tolerance Test.

Authors:  John W Newman; Sridevi Krishnan; Kamil Borkowski; Sean H Adams; Charles B Stephensen; Nancy L Keim
Journal:  Front Nutr       Date:  2022-05-11

Review 3.  Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS).

Authors:  Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-07-01       Impact factor: 4.991

Review 4.  Potential Role of Natural Plant Medicine Cyclocarya paliurus in the Treatment of Type 2 Diabetes Mellitus.

Authors:  Han Wang; Cheng Tang; Zezheng Gao; Yishan Huang; Boxun Zhang; Jiahua Wei; Linhua Zhao; Xiaolin Tong
Journal:  J Diabetes Res       Date:  2021-12-27       Impact factor: 4.011

5.  Impact of Hyperinsulinemia on Long-Term Clinical Outcomes of Percutaneous Coronary Intervention in Patients without Diabetes Who Have Acute Myocardial Syndrome.

Authors:  Qiang Tan; Ming Chen; Jia Hao; Kun Wei
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-07       Impact factor: 3.168

Review 6.  AMPK Activity: A Primary Target for Diabetes Prevention with Therapeutic Phytochemicals.

Authors:  Min-Yu Chung; Hyo-Kyoung Choi; Jin-Taek Hwang
Journal:  Nutrients       Date:  2021-11-12       Impact factor: 5.717

Review 7.  Crosstalk Communications Between Islets Cells and Insulin Target Tissue: The Hidden Face of Iceberg.

Authors:  Allan Langlois; Aurore Dumond; Julie Vion; Michel Pinget; Karim Bouzakri
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-03       Impact factor: 5.555

8.  Hua-Tan-Sheng-Jing Decoction Treats Obesity With Oligoasthenozoospermia by Up-Regulating the PI3K-AKT and Down-Regulating the JNK MAPK Signaling Pathways: At the Crossroad of Obesity and Oligoasthenozoospermia.

Authors:  Yang Dong; Yanfei Zheng; Linghui Zhu; Tianxing Li; Yuanyuan Guan; Shipeng Zhao; Qi Wang; Ji Wang; Lingru Li
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 9.  Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome.

Authors:  Dongxu Wang; Bing He
Journal:  Diabetes Metab Syndr Obes       Date:  2022-04-24       Impact factor: 3.249

10.  Comparative Phosphoproteomics of Neuro-2a Cells under Insulin Resistance Reveals New Molecular Signatures of Alzheimer's Disease.

Authors:  Dayea Kim; Yeon Suk Jo; Han-Seul Jo; Sungwon Bae; Yang Woo Kwon; Yong-Seok Oh; Jong Hyuk Yoon
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.